A study by Danish researchers including Morten Wrtz, M.D., Ph.D., Aarhus University Hospital in Denmark, used a cohort of 12,620 patients. The study found that the 30-day stroke mortality is 50.7 percent in selective serotonin reuptake inhibitors (SSRI).
The United Kingdom (UK) guidelines recommended bariatric or weight loss surgery for the treatment of obesity to reduce high blood sugar levels. Prof Francesco Rubino, King's College London, says bariatric or weight loss surgery as "the closest thing to a cure". The weight loss surgery is a very powerful treatment. The surgery involves removing part of the stomach or rerouting of the gastrointestinal tract. Weight loss surgery cause changes in gut hormone levels and better management of blood sugar. Bariatric or weight loss surgery reduces the need for oral medications or insulin injections.
Final guidelines from the National Institute for Health and Care Excellence (NICE) recommends three drugs if a person unable to use metformin or if a weight loss therapy is not beneficial. Metformin is the first drug of choice to lower body weight. But some patients will experience nausea and diarrhea (or diarrhoea) and some patients with kidney damage may not be able to use metformin. Patients can use the drugs recommended by guidelines if they can't take a sulfonylurea or pioglitazone. NICE guidelines say that the following drugs may be used on their own.
CONTOUR NEXT ONE and CONTOUR PLUS ONE are blood glucose monitoring systems (BGMS) (self-monitoring blood glucose meters, monitors, or glucometers) from Ascensia Diabetes Care. Ascensia Diabetes Care has received the CE (European) mark for glucose meters on May 17, 2016. These are easy to use wireless glucose monitoring systems. They can be connected to Smartphone via Bluetooth. The patient can monitor glucose levels. Apps can be downloaded from the Apple App Store (iOS) and Google Play (Android). Blood glucose monitors or glucometers to hit the market, wherever the blood glucose test strips are already available. Glucometers will be available in two European markets shortly and in other markets by the end of 2016.
Researchers from the Newcastle University Queen Elizabeth Hospital, Saudi Arabia found that metformin (used by the patients with diabetes) helps prevention of heart disease. Researchers developed a heart attack simulation model. They observed the formation of the new blood vessels with metformin. This process is essential for the recovery after a heart attack. Lack of oxygen in the presence of high blood glucose can prevent the formation of blood vessels. Metformin treatment helps reversal of this process and promote the formation of new blood vessels.
A patient with diabetes taking metformin may cause side effects such as weakness, anemia, tingling of fingers and toes. Metformin may also cause lower levels of A1C. This may be because of low levels of vitamin B12. A patient with diabetes taking metformin should consult a doctor for an annual checkup of vitamin B12.
A Danish study found a genetic association between psoriasis, type 2 diabetes (T2D) and obesity. The study was conducted by Dr. Ann Sophie Lonnberg, University of Copenhagen. Researchers examined the health records of 33,588 twins registered in the Danish Twin Registry. The study found that patients with psoriasis are more vulnerable to obesity and type 2 diabetes (T2D). This study was published in the journal JAMA Dermatology.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.